ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025

Core Insights - Oryzon Genomics announced that three abstracts featuring iadademstat, a selective LSD1 inhibitor, have been accepted for presentation at the 67th American Society of Hematology Annual Meeting, highlighting its potential in treating acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPNs) [1][2][4] Company Developments - The accepted abstracts showcase promising clinical activity and safety data from ongoing studies of iadademstat in combination with gilteritinib and venetoclax-azacitidine for AML patients [2][3] - Dr. Ana Limón emphasized that the addition of iadademstat enhances efficacy without increasing toxicity, particularly in the FLT3+ relapsed/refractory population, where 42% of patients had previously been treated with venetoclax [3][4] - Dr. Carlos Buesa expressed satisfaction with the selection of iadademstat abstracts for ASH 2025, underscoring its potential as a versatile epigenetic modulator in AML [4] Clinical Study Highlights - The FRIDA study (NCT05546580) is evaluating the safety and tolerability of iadademstat combined with gilteritinib in FLT3-mutated relapsed/refractory AML, with 34 patients enrolled and a 67% response rate reported [5][6] - A Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rate and 88% complete remission [7][8] - A Trial-in-progress abstract details a new randomized study of iadademstat in combination with ASTX727 for advanced MPNs, addressing the critical need for new treatments in this area [8][10] Future Directions - Oryzon is expanding the clinical development of iadademstat into non-oncological hematology indications, including trials for sickle cell disease and essential thrombocythemia [13] - The company is also exploring the use of iadademstat in solid tumors, indicating a broadening of its therapeutic applications [13]